Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Chiang J. Li, M.D., M.B.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01GM102246 (LI, CHIANG JIA) Aug 1, 2012 - Apr 30, 2017
    Transkingdom Gene Silencing
    Role: Principal Investigator
  2. R43GM096635 (LI, CHIANG JIA) May 1, 2011 - Apr 30, 2012
    Development of Specific Gene Silencing Methods and Reagents
    Role: Principal Investigator
  3. R43GM088963 (LI, CHIANG JIA) May 1, 2010 - Oct 31, 2010
    Development of aiRNA technology
    Role: Principal Investigator
  4. R43CA134097 (LI, CHIANG JIA) Jul 10, 2008 - Jun 30, 2010
    Cancer targeted therapy through bacterial RNAi
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hong SW, Jiang Y, Kim S, Li CJ, Lee DK. Target gene abundance contributes to the efficiency of siRNA-mediated gene silencing. Nucleic Acid Ther. 2014 Jun; 24(3):192-8. PMID: 24527979.
    Citations: 5     Fields:    Translation:HumansCells
  2. Lee TY, Chang CI, Lee D, Hong SW, Shin C, Li CJ, Kim S, Haussecker D, Lee DK. RNA interference-mediated simultaneous silencing of four genes using cross-shaped RNA. Mol Cells. 2013 Apr; 35(4):320-6. PMID: 23563800.
    Citations:    Fields:    Translation:HumansCells
  3. Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. Ionizing radiation induces stemness in cancer cells. PLoS One. 2012; 7(8):e43628. PMID: 22928007.
    Citations: 42     Fields:    Translation:HumansCells
  4. Li CJ, Huang SY, Wu MY, Chen YC, Tsang SF, Chyuan JH, Hsu HY. Induction of apoptosis by ethanolic extract of Corchorus olitorius leaf in human hepatocellular carcinoma (HepG2) cells via a mitochondria-dependent pathway. Molecules. 2012 Aug 03; 17(8):9348-60. PMID: 22864242.
  5. Hu X, Ghisolfi L, Keates AC, Zhang J, Xiang S, Lee DK, Li CJ. Induction of cancer cell stemness by chemotherapy. Cell Cycle. 2012 Jul 15; 11(14):2691-8. PMID: 22732500.
    Citations: 18     Fields:    Translation:HumansCells
  6. Chang CI, Lee TY, Kim S, Sun X, Hong SW, Yoo JW, Dua P, Kang HS, Kim S, Li CJ, Lee DK. Enhanced intracellular delivery and multi-target gene silencing triggered by tripodal RNA structures. J Gene Med. 2012 Feb; 14(2):138-46. PMID: 22228611.
    Citations: 7     Fields:    Translation:HumansCells
  7. Chang CI, Lee TY, Dua P, Kim S, Li CJ, Lee DK. Long double-stranded RNA-mediated RNA interference and immunostimulation: long interfering double-stranded RNA as a potent anticancer therapeutics. Nucleic Acid Ther. 2011 Jun; 21(3):149-55. PMID: 21749291.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  8. Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK. Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther. 2011 Jun; 21(3):125-31. PMID: 21749289.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  9. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010 Jun; 9(6):1544-53. PMID: 20484018.
    Citations: 101     Fields:    Translation:HumansAnimalsCells
  10. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, Rogoff HA, Ban C, Kim S, Li CJ, Lee DK. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009 Apr; 17(4):725-32. PMID: 19156133.
    Citations: 29     Fields:    Translation:HumansCells
  11. Xiang S, Keates AC, Fruehauf J, Yang Y, Guo H, Nguyen T, Li CJ. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi). Methods Mol Biol. 2009; 487:147-60. PMID: 19301646.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  12. Sun X, Rogoff HA, Li CJ. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol. 2008 Dec; 26(12):1379-82. PMID: 19029911.
    Citations: 38     Fields:    Translation:HumansCells
  13. Uppalapati U, Ashwell MA, Leggett DS, Li CJ. High-content fluorescent-based assay for screening activators of DNA damage checkpoint pathways. J Biomol Screen. 2008 Jul; 13(6):538-43. PMID: 18566483.
    Citations: 3     Fields:    Translation:HumansCells
  14. Keates AC, Fruehauf J, Xiang S, Li CJ. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery. Biotechnol Genet Eng Rev. 2008; 25:113-27. PMID: 21412352.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  15. Keates AC, Fruehauf JH, Xiang S, Parker PD, Li CJ. Cequent Pharmaceuticals, Inc.: the biological pitcher for RNAi therapeutics. Pharmacogenomics. 2007 Jul; 8(7):867-71. PMID: 18240911.
    Citations: 4     Fields:    Translation:Humans
  16. Li CJ. Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. J Cell Physiol. 2006 Dec; 209(3):695-700. PMID: 17001685.
    Citations:    Fields:    Translation:HumansAnimalsCells
  17. Sun X, Li Y, Li W, Zhang B, Wang AJ, Sun J, Mikule K, Jiang Z, Li CJ. Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle. 2006 Sep; 5(17):2029-35. PMID: 16969131.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  18. Yang Y, Fruehauf J, Xiang S, Li CJ. Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients. Cell Cycle. 2006 Jul; 5(13):1443-7. PMID: 16855398.
    Citations: 5     Fields:    Translation:HumansCells
  19. Xiang S, Fruehauf J, Li CJ. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol. 2006 Jun; 24(6):697-702. PMID: 16699500.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  20. Wang A, Li CJ, Reddy PV, Pardee AB. Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation. Cancer Res. 2005 Sep 01; 65(17):7809-14. PMID: 16140949.
    Citations: 6     Fields:    Translation:HumansCells
  21. Chen CR, Wang W, Rogoff HA, Li X, Mang W, Li CJ. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 2005 Jul 15; 65(14):6017-21. PMID: 16024600.
    Citations: 12     Fields:    Translation:HumansCells
  22. Pardee AB, Li CJ, Reddy GP. Regulation in S phase by E2F. Cell Cycle. 2004 Sep; 3(9):1091-4. PMID: 15467444.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  23. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2674-8. PMID: 12598645.
    Citations: 19     Fields:    Translation:HumansCells
  24. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep; 2(3):227-42. PMID: 12188909.
    Citations: 34     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Li's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (162)
Co-Authors (3)
Similar People (60)
Same Department 
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.